261 related articles for article (PubMed ID: 9737837)
21. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.
Hemeryck A; Belpaire FM
Curr Drug Metab; 2002 Feb; 3(1):13-37. PubMed ID: 11876575
[TBL] [Abstract][Full Text] [Related]
22. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
23. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.
Sproule BA; Naranjo CA; Brenmer KE; Hassan PC
Clin Pharmacokinet; 1997 Dec; 33(6):454-71. PubMed ID: 9435993
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.
Baumann P
Clin Pharmacokinet; 1996 Dec; 31(6):444-69. PubMed ID: 8968657
[TBL] [Abstract][Full Text] [Related]
25. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in The Netherlands: a multivariate analysis.
Pathiyal A; Hylan TR; Jones JK; Davtian D; Sverdlov L; Keyser M
Clin Ther; 1997; 19(4):798-810. PubMed ID: 9377622
[TBL] [Abstract][Full Text] [Related]
26. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
27. Pre-clinical drug-drug interactions (DDIs) of gefitinib with/without losartan and selective serotonin reuptake inhibitors (SSRIs): citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine.
Luong TT; Powers CN; Reinhardt BJ; Weina PJ
Curr Res Pharmacol Drug Discov; 2022; 3():100112. PubMed ID: 35756846
[TBL] [Abstract][Full Text] [Related]
28. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Bron MS
Clin Ther; 2006 Feb; 28(2):297-305; discussion 296. PubMed ID: 16678651
[TBL] [Abstract][Full Text] [Related]
29. The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K
Clin Investig; 1993 Dec; 71(12):1002-9. PubMed ID: 8124052
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.
Serrano-Blanco A; Pinto-Meza A; Suárez D; Peñarrubia MT; Haro JM;
Acta Psychiatr Scand Suppl; 2006; (432):39-47. PubMed ID: 17087814
[TBL] [Abstract][Full Text] [Related]
31. SSRI antidepressant drug use patterns in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
Med Care; 1999 Apr; 37(4 Suppl Lilly):AS36-44. PubMed ID: 10217392
[TBL] [Abstract][Full Text] [Related]
32. Antidepressant medication change in a clinical treatment setting: a comparison of the effectiveness of selective serotonin reuptake inhibitors.
Nurnberg HG; Thompson PM; Hensley PL
J Clin Psychiatry; 1999 Sep; 60(9):574-9. PubMed ID: 10520974
[TBL] [Abstract][Full Text] [Related]
33. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
[TBL] [Abstract][Full Text] [Related]
34. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine.
Charlier C; Broly F; Lhermitte M; Pinto E; Ansseau M; Plomteux G
Ther Drug Monit; 2003 Dec; 25(6):738-42. PubMed ID: 14639062
[TBL] [Abstract][Full Text] [Related]
35. Pre-clinical evaluation of CYP 2D6 dependent drug-drug interactions between primaquine and SSRI/SNRI antidepressants.
Jin X; Potter B; Luong TL; Nelson J; Vuong C; Potter C; Xie L; Zhang J; Zhang P; Sousa J; Li Q; Pybus BS; Kreishman-Deitrick M; Hickman M; Smith PL; Paris R; Reichard G; Marcsisin SR
Malar J; 2016 May; 15(1):280. PubMed ID: 27188854
[TBL] [Abstract][Full Text] [Related]
36. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
37. The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly.
Bahar MA; Hak E; Bos JHJ; Borgsteede SD; Wilffert B
Pharmacoepidemiol Drug Saf; 2017 Jul; 26(7):752-765. PubMed ID: 28345306
[TBL] [Abstract][Full Text] [Related]
38. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment.
Fava M; Judge R; Hoog SL; Nilsson ME; Koke SC
J Clin Psychiatry; 2000 Nov; 61(11):863-7. PubMed ID: 11105740
[TBL] [Abstract][Full Text] [Related]
39. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
Strawn JR; Mills JA; Croarkin PE
J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
[No Abstract] [Full Text] [Related]
40. Pharmacokinetic interactions of antidepressants.
Richelson E
J Clin Psychiatry; 1998; 59 Suppl 10():22-6. PubMed ID: 9720479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
